Affordable Access

Publisher Website

The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer

Authors
Journal
Advances in Urology
1687-6369
Publisher
Hindawi Publishing Corporation
Publication Date
Volume
2012
Identifiers
DOI: 10.1155/2012/248607
Keywords
  • Review Article
Disciplines
  • Medicine

Abstract

An association between the metabolic syndrome and reduced testosterone levels has been identified, and a specific inverse relationship between insulin and testosterone levels suggests that an important metabolic crosstalk exists between these two hormonal axes; however, the mechanisms by which insulin and androgens may be reciprocally regulated are not well described. Androgen-dependant gene pathways regulate the growth and maintenance of both normal and malignant prostate tissue, and androgen-deprivation therapy (ADT) in patients exploits this dependence when used to treat recurrent and metastatic prostate cancer resulting in tumour regression. A major systemic side effect of ADT includes induction of key features of the metabolic syndrome and the consistent feature of hyperinsulinaemia. Recent studies have specifically identified a correlation between elevated insulin and high-grade PCa and more rapid progression to castrate resistant disease. This paper examines the relationship between insulin and androgens in the context of prostate cancer progression. Prostate cancer patients present a promising cohort for the exploration of insulin stabilising agents as adjunct treatments for hormone deprivation or enhancers of chemosensitivity for treatment of advanced prostate cancer.

There are no comments yet on this publication. Be the first to share your thoughts.